Department of Internal Medicine, Seoul National University College of medicine, Seoul, Republic of Korea.
Endocr J. 2012;59(11):1021-30. doi: 10.1507/endocrj.ej12-0128. Epub 2012 Jul 14.
The best treatment option for recurrent papillary thyroid carcinoma (PTC) is reoperation when the recurrent lesion is locoregional. The prognostic significance of serum thyroglobulin (Tg) levels before reoperation and the association between the outcome of reoperation and Tg level remain unclear. Our study aimed to determine the outcomes of patients who underwent reoperation and their association with serum Tg levels. We retrospectively studied 79 patients with PTC with locoregional recurrence whose whole-body scan results were negative for any recurrence but whose serum Tg levels were detectable after first-line treatment. All the patients underwent reoperation and follow-up examinations, which involved serial serum Tg measurements after thyroxine withdrawal (T4-off Tg), neck ultrasonography, chest computed tomography, and/or fluorodeoxyglucose-positron emission tomography, to detect further recurrence. During the median follow-up duration of 89 months (range, 38-332 months), 30 patients (38.0%) experienced a second recurrence even after the reoperation. Among all patients, only 12 whose Tg levels decreased postoperatively to undetectable levels showed no recurrence. Most recurrences were detected in the patients with high T4-off Tg levels after the reoperation (T4-off Tg level (ng/mL), number of patients with recurrence, %: <1, 0/12, 0%; 1-10, 9/31, 33.3%; >10, 16/22, 72.7%; P < 0.001). In conclusion, recurrence occurred in 38.0% of the patients even after the reoperation. The postoperative T4-off Tg level was a good indicator of recurrence after the reoperation. Therefore, patients who experience recurrence should undergo follow-up examinations that involve routine measurements of T4-off Tg levels, especially when postreoperative values exceed 10 ng/mL.
对于局部复发的复发性甲状腺乳头状癌(PTC),最佳治疗选择是再次手术。手术前血清甲状腺球蛋白(Tg)水平的预后意义以及再次手术后结局与 Tg 水平之间的关系尚不清楚。我们的研究旨在确定接受再次手术的患者的结局及其与血清 Tg 水平的关系。我们回顾性研究了 79 例局部复发的 PTC 患者,这些患者的全身扫描结果均未显示任何复发,但在一线治疗后可检测到血清 Tg 水平。所有患者均接受了再次手术和随访检查,包括甲状腺素停药后(T4 停药 Tg)的系列血清 Tg 测量、颈部超声、胸部计算机断层扫描和/或氟脱氧葡萄糖正电子发射断层扫描,以检测进一步的复发。在中位数为 89 个月(范围 38-332 个月)的随访期间,30 例患者(38.0%)在再次手术后仍出现第二次复发。在所有患者中,只有 12 例患者术后 Tg 水平降至不可检测水平,无复发。大多数复发发生在术后 T4 停药 Tg 水平较高的患者中(T4 停药 Tg 水平(ng/mL),复发患者数,%:<1,0/12,0%;1-10,9/31,33.3%;>10,16/22,72.7%;P<0.001)。总之,即使在再次手术后,仍有 38.0%的患者复发。术后 T4 停药 Tg 水平是再次手术后复发的良好指标。因此,当术后 Tg 水平超过 10ng/mL 时,复发的患者应接受包括常规 T4 停药 Tg 水平测量在内的随访检查。